Syridex Bio is an impact-driven, life sciences-focused firm investing in therapies that accelerate global health equity by addressing the needs of underserved communities.
We draw on our deep relationships across the global pharmaceutical and biotech industries to source innovative, best-in-class clinical stage or near-clinical stage therapies for diseases that disproportionately affect underserved communities. Then, we invest in development to bring to market novel drugs and treatments that might otherwise go undeveloped.
We invest along two primary strategies: venture creation and private equity.
- Venture Creation: Building sustainable companies around innovative products we acquire from life sciences companies and institutions
- Private Equity: Privatizing and creating value for undervalued public pharmaceutical and biotechnology companies
Our team is focused on accelerating health equity and eliminating health disparities around the world.